Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Livius Penter

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Journal of Hematology & Oncology|February 13, 2025
First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancerRoman M Shapiro, Michal Sheffer, Matthew A Booker, et al.
Science Immunology|January 24, 2025
Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapyKatie Maurer, Cameron Y Park, Shouvik Mani, et al.
Blood|November 4, 2022
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settingsJacqueline S Garcia, Yael Flamand, Livius Penter, et al.
Nature|December 1, 2025
Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantationChristian Gaebler, Samad Kor, Kristina Allers, et al.
Nature Biotechnology|August 21, 2024
Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantationNicoletta Cieri, Nidhi Hookeri, Kari Stromhaug, et al.
Blood|March 15, 2021
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantationLivius Penter, Yi Zhang, Alexandra Savell, et al.
Blood|January 27, 2023
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid diseaseLivius Penter, Yang Liu, Jacquelyn O Wolff, et al.
Blood Cancer Discovery|December 5, 2022
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic VulnerabilitiesElisa Ten Hacken, Tomasz Sewastianik, Shanye Yin, et al.
The Journal of Clinical Investigation|June 25, 2024
Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in miceNana Talvard-Balland, Lukas M Braun, Karen O Dixon, et al.
Science Immunology|September 8, 2023
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancerGiacomo Oliveira, Ann Marie Egloff, Alexander B Afeyan, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Journal of Hematology & Oncology|February 13, 2025
First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancerRoman M Shapiro, Michal Sheffer, Matthew A Booker, et al.
Science Immunology|January 24, 2025
Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapyKatie Maurer, Cameron Y Park, Shouvik Mani, et al.
Blood|November 4, 2022
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settingsJacqueline S Garcia, Yael Flamand, Livius Penter, et al.
Nature|December 1, 2025
Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantationChristian Gaebler, Samad Kor, Kristina Allers, et al.
Nature Biotechnology|August 21, 2024
Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantationNicoletta Cieri, Nidhi Hookeri, Kari Stromhaug, et al.
Blood|March 15, 2021
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantationLivius Penter, Yi Zhang, Alexandra Savell, et al.
Blood|January 27, 2023
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid diseaseLivius Penter, Yang Liu, Jacquelyn O Wolff, et al.
Blood Cancer Discovery|December 5, 2022
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic VulnerabilitiesElisa Ten Hacken, Tomasz Sewastianik, Shanye Yin, et al.
The Journal of Clinical Investigation|June 25, 2024
Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in miceNana Talvard-Balland, Lukas M Braun, Karen O Dixon, et al.
Science Immunology|September 8, 2023
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancerGiacomo Oliveira, Ann Marie Egloff, Alexander B Afeyan, et al.
Pageof 5